Merck

Last updated January 31, 2026

124

Innovation Areas

5,362

Inventors

Collaborations

Imidazolonylquinoline atm kinase inhibitors: MerckRecent Research Landscape

Uncontrolled DNA damage repair allows tumor survival during radiotherapy, which these specific chemical scaffolds mitigate by blocking ATM kinase activity. Precise inhibition of this signaling pathway increases the sensitivity of cancer cells to treatment while reducing systemic toxicity.

What technical problems is Merck addressing in Imidazolonylquinoline atm kinase inhibitors?

Uncontrolled cellular dna repair

(5)evidences

Abnormal cellular growth and genomic instability drive tumor progression. Inhibiting ATM kinase activity disrupts the DNA damage response to halt tumor survival.

Poor drug metabolic stability

(1)evidences

Helminthic parasites exhibit high survival rates and resistance to standard treatments within host organisms. Overcoming this biological persistence is necessary to prevent chronic disease and transmission.